Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403117 | 0.86 | PDE3B (0.43) | PDE3BPDE3AAKR1C3AKR1C2EPHX2 | |
| SCHEMBL8506193 | 0.86 | ACE2 (0.48) | SRD5A2ACE2EPHX2MEN1KMT2A | |
| SCHEMBL27999972 | 0.84 | SRD5A2 (0.40) | SRD5A2ACE2AKR1C3AKR1C2EPHX2 | |
| SCHEMBL1806648 | 0.84 | NOTUM (0.55) | PDE3BPDE3AEPHX2PPARGLMNA | |
| SCHEMBL6293963 | 0.83 | ALDH1A1 (0.46) | SRD5A2ACE2AKR1C3AKR1C2EPHX2 | |
| SCHEMBL1697891 | 0.82 | EPHX2 (0.44) | SRD5A2ACE2EPHX2SMN1; SMN2P4HB | |
| SCHEMBL16121258 | 0.82 | ACE2 (0.53) | SRD5A2ACE2AKR1C3AKR1C2EPHX2 | |
| SCHEMBL9184815 | 0.79 | EPHX2 (0.41) | SRD5A2ACE2EPHX2SMN1; SMN2P4HB | |
| SCHEMBL3128273 | 0.79 | EPHX2 (0.50) | ACE2EPHX2MEN1LMNAHPGD | |
| SCHEMBL3944077 | 0.78 | ALDH1A1 (0.50) | SRD5A2ACE2AKR1C3AKR1C2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102686571-B | tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-103012390-B | As the indole derivatives of S1P1 receptor stimulant | GLAXO GROUP LTD. (GB) | 2015-08-26 | — | — | CN | disclosed |
| EP-2003132-B1 | Oxadiazole derivatives as S1P1 agonists | ASTELLAS PHARMA INC (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| CN-101611033-A | Indole derivatives as S1P1 receptor agonists | GLAXO GROUP LTD (GB) | 2009-12-23 | — | — | CN | disclosed |
| EP-2091950-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| EP-2091949-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074821-A1 | INDOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048639-A1 | OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | SRD5A2 893/4885PDE3B 122/4885PDE3A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.